16 results about "Human intestine" patented technology

The invention discloses an easily absorbable organic calcium powder containing mineral elements and a preparation process thereof, and the raw materials comprise, by weight, 50-70 parts of an organic calcium source, 20-30 parts of a plant protein source, 5-10 parts of a polybasic amino acid chelate, 0.01-0.03 part of vitamin D3, 1-3 parts of trace mineral elements, 0.5-1.5 parts of compound protease, 0.1-0.3 part of a food-grade surfactant, and 100-150 parts of deionized water. The invention relates to the technical field of nutritional supplements. According to the mineral element-containing easy-to-absorb organic calcium powder and the preparation process, vegetable protein is converted into amino acid through biological enzymolysis, the amino acid and calcium carbonate are subjected to a chelation reaction to generate amino acid chelated calcium, and compared with traditional organic calcium, chelated calcium is more easily absorbed by human intestinal tracts; meanwhile, calcium, magnesium and phosphorus are synergistically matched, magnesium can activate vitamin D3, the vitamin D3 further promotes absorption of calcium, phosphorus and calcium form a reasonable proportion, deposition of calcium in bones is enhanced, and calcium ions can be absorbed in intestinal tracts without depending on gastric acid by adopting a bicyclic stable chelating structure.

The invention belongs to the technical field of bioengineering, and discloses a specific identification primer and method for lactobacillus curvatus in human intestinal tracts and application. The identification primer comprises an upstream primer COG3825F1 and a downstream primer COG3825R1, the nucleotide sequence of the upstream primer COG3825F1 is 5 '-GTCACAACAAGACCGATTT-3', and the nucleotide sequence of the downstream primer COG3825R1 is 5 '-CTGTTTCTACAACTTGTGCT-3', and the nucleotide sequence of the upstream primer COG3825F1 and the nucleotide sequence of the downstream primer COG3825R1 are 5 '-GTCACAACAAGACCGATTT-3'. The specific COG3825 gene of the lactobacillus flexus is screened to serve as a target sequence design primer, and PCR, gel electrophoresis and qPCR verification show that the primer has extremely high specificity and sensitivity and can accurately distinguish the lactobacillus flexus from the related lactobacillus and other common intestinal bacteria under the complex micro-ecological background of the human intestinal tract; the identification method based on the primer is easy and convenient to operate and accurate in result, qualitative and quantitative detection of the lactobacillus brevis in human intestinal samples, food samples and other environment samples can be achieved, and important technical support is provided for related research, application development and micro-ecological monitoring of the lactobacillus brevis.

The invention relates to a preparation method of a low-calorie and low-carbohydrate weight-losing main food, which is characterized in that the low-calorie and low-carbohydrate weight-losing main food with the content of 200-350 kilocalories is produced by utilizing the functional effect that insoluble coarse dietary fibers can be expanded into about 7 times of volume after entering human intestinal tracts and absorbing water; enteral emptying is prolonged, so that hunger sensation can be reduced, and happiness of the human body is increased. Food with low calorie and extremely low carbohydrate content is produced and processed by using a method for removing components except insoluble coarse dietary fibers by using a biological function containing cellulase and a compound enzyme of the cellulase and the like; the invention relates to a preparation method of dietary fiber food such as soybean dreg powder, wheat bran powder and the like, wherein the intake of the soybean dreg powder is reduced by 500-1000 kilocalories per day on the basis of target energy.

The invention discloses a specific primer for identifying sake lactobacillus brevis, which comprises an upstream primer COG3681F1: 5 '-SCTGCGATGTCCAACTCT-3', and a downstream primer COG3681F1: 5 '-SCTGCGATGTCCACTCT-3', and the Tm is 55 DEG C; the invention discloses a kit for detecting lactobacillus sake brevibacillus, which comprises a forward primer COG3681F1, a reverse primer COG3681R1: 5 '-CGAATCAGCTGTTCCTCAGT-3', Tm of which is 55 DEG C. A probe matched with the primers COG3681F1 and COG3681R1 is 5 '-CTGCCGCTACGCTGACCG-3', the 5'end is marked with an FAM report fluorophore, and the 3 'end is marked with a BHQ1 quenching fluorophore. According to the kit, the efficient and specific detection of lactobacillus sake brevibacillus is realized, and whether the strain is lactobacillus sake brevibacillus can be judged in a short time.

The invention relates to an establishment method of a high-fat induced intestinal organ injury model and an injury intervention method for the model. The establishment method comprises the following steps: step A, preparation: preparing colon cells, PBMC cells and an organ-like culture chip for later use; step B, colon barrier construction: inoculating colon cells to the surface of a barrier membrane on the lower side of a culture chip by using an organoid culture chip to obtain a colon barrier model; step C, constructing a co-culture model, and inoculating PBMC cells to the basal side of the colon barrier on the basis of the colon barrier to obtain a human colon barrier-PBMC co-culture model; d, constructing a damage model, and performing damage treatment on the co-culture model by using a treating fluid to obtain the damage model; according to the invention, the barrier function organ-like chip is used, a human intestinal cell-PBMC co-culture model is formed by utilizing human intestinal organs and PBMC cells, and OXLDL / palmitic acid can play a role in an injured intestinal organ barrier model and form a high-fat induced intestinal organ injury model through the prepared injury treating fluid.

This invention discloses an intelligent bionic artificial anus system, comprising: a sphincter module, a pressure sensor, and a controller. The pressure sensor and controller are disposed within the sphincter module. The sphincter module is located on the outer side of the human intestine and constricts the intestine. The pressure sensor detects a first pressure emanating from inside the intestine and sends the first pressure value to the controller. The controller issues an opening command when the first pressure value meets a first condition. The sphincter module reduces the external pressure applied to the intestine based on the opening command, causing the intestine to open. The controller issues a closing command when the first pressure value meets a second condition. The sphincter module closes the intestine based on the closing command. This allows patients who have had their anus removed to regain anal function, enabling them to defecate, work, live, and exercise normally without the need for a stoma, thus improving their quality of life.

The invention discloses an intestinal microbial marker combination for noninvasive diagnosis of intrahepatic cholestasis and application of the intestinal microbial marker combination, and belongs to the technical field of medical treatment. According to the invention, by integrating metagenome sequencing and a machine learning algorithm, a group of intestinal microbial marker combination composed of 12 bacterial species is screened; the bacillus subtilis specifically comprises atypical virenoccus virens, Wilbionan isonibacterium, Brawtella, mucophilic protein anaerobic corynebacterium, bacteroides simplex, a clostridium AT4 strain, sargassum purpurascens, lawsonia sacchariflora, clostridium enteric, actinomycetes grignard, brassicaceae marsi Q3528 and bile vowenii. The AUC of a diagnosis model constructed based on the marker combination on an independent test set reaches 0.871, and the sensitivity and the specificity reach 86.7% and 81.3% respectively. The invention provides a non-invasive, simple, convenient and accurate auxiliary diagnosis tool for intrahepatic cholestasis, and has excellent clinical transformation prospects.

Provided herein are probiotic compositions and methods for treating animals or humans, or human or animal feed, or a surface in contact therewith comprising: feeding or providing a feed, supplement, additive, or food to animals or humans with a composition comprising one or more probiotic bacteria, supernatant, extract, broth, or fermentate thereof, selected from L28, L3AL3 A, L20-B, J7, J14, J27, J43, J16, J34, J25, L5-A and J19 provided in an amount sufficient to be at least one of: bactericidal against bacteria selected from at least one of: spore-forming bacteria, gram positive bacteria, gram negative bacteria, or combinations thereof, in animal or human intestines, improve gut structure, reduce gut inflammation, improved nutrient digestibility, improve mineral absorption and growth performance, reduce carriage, reduce fecal shedding, or reduce gut infection and inflammation.

The invention belongs to the technical field of biological medicine, and particularly relates to an intestinal fungus microorganism model for noninvasive diagnosis of an atrial fibrillation patient and application of the intestinal fungus microorganism model. The invention provides an intestinal tract fungal microorganism model (fungal microorganism distinguishing model) for distinguishing atrial fibrillation patients and non-atrial fibrillation patients, which consists of 15 fungal microorganism genes as shown in SEQ ID NO: 1-15, and the fungal microorganism genes are enriched in human intestinal tracts. The intestinal fungus microbial gene distinguishing model disclosed by the invention realizes good distinguishing ability between atrial fibrillation patients and non-atrial fibrillation patients, and also verifies the feasibility, applicability and universality of the distinguishing model in different regions in China.

The present application relates to a kind of preparation method of fecal bacteria for intestinal flora transplantation.The present application includes the following steps: (1) preparation of intestinal flora reticular carrier; (2) preparation of intestinal flora suspension; (3) preparation of bionic intestine; (4) in vitro continuous culture of intestinal flora; (5) collection after intestinal flora culture.The present application provides a preparation method of fecal bacteria for intestinal flora transplantation, which realizes in vitro culture of intestinal flora by simulating the living environment of intestinal flora in human intestine, ensures the stability of flora quality and yield, eliminates the time limit of intestinal flora transplantation treatment, and greatly improves the timeliness of clinical application.The intestinal flora prepared by the present application has large yield and high activity.Furthermore, the intestinal flora of the present application has obvious improvement in relieving weight loss of inflammatory bowel disease patients, relieving food utilization coefficient decline of inflammatory bowel disease patients, relieving red blood cell quantity decline of inflammatory bowel disease patients, reducing white blood cell quantity of inflammatory bowel disease patients and improving intestinal beneficial bacteria content.

This invention discloses a high-purity, multifunctional probiotic powder and its preparation method. Based on the different characteristics of lactic acid bacteria, Bacillus subtilis, and actinomycetes, this invention employs different methods for their respective proliferation. This not only avoids potential mutual interference and contamination during their individual proliferation processes but also achieves high viable cell counts while maintaining high purity, and the high viable cell count is maintained even after mixing. This invention mixes the proliferated bacterial powders in a reasonable ratio, allowing lactic acid bacteria to be the dominant strain while fully utilizing the functional characteristics of each of the three bacteria: lactic acid bacteria are anaerobic, while Bacillus subtilis and actinomycetes are aerobic. The latter can absorb oxygen released by the former, ensuring that in the anaerobic environment of the human intestine, Bacillus subtilis and actinomycetes remain active rather than dormant, generating resistant endospores through synergistic action with lactic acid bacteria.

The present invention provides a method for producing a sarcopenia-inhibiting food product readily available to general consumers, the sarcopenia-inhibiting food product, and a muscle-enhancing food product. In order to solve this problem, this method for producing the sarcopenia-inhibiting food product performs production by fermentation of American ginseng using a microbial group containing at least one of lactic acid bacteria and bifidobacteria. The microbial group preferably contains lactic acid bacteria capable of growing in human intestines. The fermentation is preferably performed for 36-120 hours, inclusive. This sarcopenia-inhibiting food product and this muscle-enhancing food product contain a fermented product of American ginseng using a microbial group containing at least one of lactic acid bacteria and bifidobacteria.

The invention discloses a lactobacillus casei specific recognition primer and probe based on an L-fucosylgyrase gene and application of the lactobacillus casei specific recognition primer and probe. The sequences of a primer pair are COG4154F1 and COG4154R1, and the amplified fragment is 239 bp; the sequence of the probe is 5 '-CYGCTTGMACCACCGCCTGA-3', and the probe is marked with an FAM / BHQ1 fluorophore. The primer and the probe have high specificity and sensitivity, and are suitable for qualitative and quantitative detection of the lactobacillus casei in human intestinal tracts, dairy products and the like.

Animal feed additives are described comprising polypeptides having alkaline phosphatase activity wherein the selected polypeptides have activity against related biological targets, which polypeptides are thermally stable and have a high three-dimensional similarity between each other and to human intestinal alkaline phosphatase and are very close to each other on the phylogenetic tree.

The invention disclosed herein generally relates to methods and systems for converting stem cells into specific tissue(s) or organ(s) through directed differentiation. In particular, the invention disclosed herein relates to methods and systems for promoting human intestinal tissue (e.g., human intestinal organoid tissue) comprising epithelium, stroma, neurons, endothelial cells, and organized smooth muscle, and interstitial cells of Cajal (ICCs).

The invention discloses a group of primers for identifying the specificity of plant lactobacillus in human intestinal tracts. The group of primers comprises an upstream primer COG3419F1 and a downstream primer COG3419R1, the nucleotide sequence of the upstream primer COG3419F1 is 5 '-CGCCACAGCAAGTAACCAT-3', and the nucleotide sequence of the downstream primer COG3419F1 is 5 '-CGCCACAGCAAGTAACCAT-3 The nucleotide sequence of the downstream primer COG3419R1 is 5 '-GACCATACCCAAGTGCCAT-3', and the nucleotide sequence of the downstream primer COG3419R1 is 5 '-GACCATACCCAAGTGCCAT-3 The probe is a sequence designed aiming at the specific COG3419 gene segment of the plant lactobacillus; the specific COG3419 gene of the phytobacterium plantarum is screened as a target sequence, the primer and the probe with high specificity and sensitivity are designed, the phytobacterium plantarum and other intestinal bacteria can be accurately distinguished under the background of complex microorganisms of the human intestinal tract, and rapid qualitative detection and accurate quantitative analysis of the phytobacterium plantarum are achieved; the primer, the probe and the detection method can also be extensively applied to detection of the phytobacterium plantarum in various samples such as food, environment and the like.